Presepsin as a predictive biomarker of severity in COVID‐19: A case series-Reference-Cited by-同舟云学术

Presepsin as a predictive biomarker of severity in COVID‐19: A case series

Published:2020-06-24 Issue:1 Volume:93 Page:99-101
ISSN:0146-6615
Container-title:Journal of Medical Virology
language:en
Short-container-title:J Med Virol

Author:

Fukada Ai¹,Kitagawa Yutaro¹,Matsuoka Masaru¹,Sakai Jun²,Imai Kazuo²^ORCID,Tarumoto Norihito²,Orihara Yuta¹,Kawamura Rieko¹,Takeuchi Shinichi¹,Maesaki Shigefumi²,Maeda Takuya¹³^ORCID

Affiliation:

1. Department of Clinical Laboratory Saitama Medical University Hospital Saitama Japan

2. Department of Infectious Disease and Infection Control Saitama Medical University Saitama Japan

3. Department of Laboratory Medicine Saitama Medical University Saitama Japan

Publisher

Wiley

Subject

Infectious Diseases,Virology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.26164

Reference7 articles.

1. N.H.C.o.t.P.s.R.o. China. The notice of launching guideline on diagnosis and treatment of the novel coronavirus pneumonia (NCP). Revised version of the 5th ed (2020).

2. Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study

3. Presepsin (soluble CD14 subtype) and procalcitonin levels for mortality prediction in sepsis: data from the Albumin Italian Outcome Sepsis trial

4. National Institute of Infectious Diseases. Manual for the detection of pathogen 2019‐nCoV Ver.2.6.https://www.niid.go.jp/niid/ja/diseases/ka/corona-virus/2019-ncov/2484-idsc/9403-labo-manual.html

5. Presepsin in risk stratification of SARS-CoV-2 patients

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase 2, randomized, double-blind, placebo-controlled multi- center trial of the clinical and biological effects of anti-CD14 treatment in hospitalized patients with COVID-19 pneumonia;EBIOMEDICINE;2023

2. Phase 2, randomized, double-blind, placebo-controlled multi-center trial of the clinical and biological effects of anti-CD14 treatment in hospitalized patients with COVID-19 pneumonia;eBioMedicine;2023-07

3. Endotheliopathy in Acute COVID-19 and Long COVID;International Journal of Molecular Sciences;2023-05-04

4. Potential predictors of severe course and outcome of community-acquired pneumonia;PULMONOLOGIYA;2023-04-11

5. Daily combined measurement of platelet count and presepsin concentration can predict in-hospital death of patients with severe coronavirus disease 2019 (COVID-19);International Journal of Hematology;2023-03-15